Source: China – South China Morning PostChina’s front-running experimental drug to treat Covid-19 has suffered a setback, with a late-stage trial on outpatients failing because of a low number of hospitalisations.Kintor Pharma’s candidate Proxalutamide – administered as a simple pill – has been undergoing phase 3 trials in the US, Brazil, China and the European Union to test its safety and efficacy for prostate and breast cancers, as well as Covid-19.“Statistical criteria were not met at an interim analysis of the phase 3 outpatient…Read More